Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 399

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 399
---
 value and (B) 0.361. The “fair market value” as used in the preceding sentence shall mean the volume weighted average price of the shares of ParentCo Common Stock for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.

#### Private Warrants
At Closing, there will be 835,555 Private Warrants outstanding held by Cantor. Each Private Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share. If Iris does not complete a business combination by March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board), the Private Warrants will expire worthless.

Under the Sponsor Forfeiture Agreement between the Sponsor and Iris and Liminatus, the Sponsor has agreed to forfeit 4,177,778 of its Private Placement Warrants at Closing.

<div align='center'>217</div>

TABLE OF CONTENTS

The Private Warrants are identical to the Public Warrants except that they will be non-redeemable and exercisable on a cashless basis for as long as the Private Warrants are held by Cantor, the representative of the underwriters, or its permitted transferees. Additionally, for so long as the Private Warrants are held by Cantor or its designees or affiliates, they may not be exercised after five years from the closing of the IPO.

<div align='center'>218</div>

TABLE OF CONTENTS

### BENEFICIAL OWNERSHIP OF SECURITIES
The following table sets forth information regarding: (i) the actual beneficial ownership of Iris common stock as of January 2, 2025 based on information obtained from the persons named below, with respect to the beneficial ownership of Iris common stock, which is prior to the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement and (ii) expected beneficial ownership of ParentCo Common Stock immediately following the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement, assuming that: (x) no shares of Iris Class A Common Stock are redeemed and (y) assuming that all shares of Iris Class A Common Stock are redeemed for cash and excluding the potential dilutive effect of the exercise of the ParentCo warrants after the closing held by:

•

each person or “group” (as such term is used in Section 13(d)(3) of the Exchange Act